p.106 抽出テキスト

507. Isobe S, Kataoka M, Aimi Y, et al. Improved Survival of Patients with Pulmonary Arterial Hypertension with BMPR2 Mutations in the Last Decade. Am J Respir Crit Care Med 2016; 193: 1310- 1314. PMID: 27248591 508. Evans JD, Girerd B, Montani D, et al. BMPR 2 mutations and survival in pulmonary arterial hypertension: an individual participant data meta-analysis. Lancet Respir Med 2016; 4: 129- 137. PMID: 26795434 509. Galiè N, Humbert M, Vachiery JL, et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Respir J 2015; 46: 903-975. PMID: 26318161 510. Galiè N, Humbert M, Vachiery JL, et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Heart J 2016; 37: 67-119. PMID: 26320113 511. Hiraide T, Kataoka M, Suzuki H, et al. Poor outcomes in carriers of the RNF 213 variant (p.Arg 4810Lys) with pulmonary arterial hypertension. J Heart Lung Transplant 2020; 39: 103-112. PMID: 31542298 512. Fukushima H, Takenouchi T, Kosaki K. Homozygosity for moyamoya disease risk allele leads to moyamoya disease with extracranial systemic and pulmonary vasculopathy. Am J Med Genet A 2016; 170: 2453-2456. PMID: 27375007 513. Hiraide T, Suzuki H, Momoi M, et al. RNF 213-Associated Vascular Disease: A Concept Unifying Various Vasculopathies. Life (Basel) 2022; 12: . PMID: 35455046 514. Eyries M, Montani D, Girerd B, et al. EIF 2AK 4 mutations cause pulmonary veno-occlusive disease, a recessive form of pulmonary hypertension. Nat Genet 2014; 46: 65-69. PMID: 24292273 515. Hadinnapola C, Bleda M, Haimel M, et al. Phenotypic Characterization of EIF2AK4 Mutation Carriers in a Large Cohort of Patients Diagnosed Clinically With Pulmonary Arterial Hypertension. Circulation 2017; 136: 2022-2033. PMID: 28972005 516. Best DH, Sumner KL, Smith BP, et al. EIF 2AK 4 Mutations in Patients Diagnosed With Pulmonary Arterial Hypertension. Chest 2017; 151: 821-828. PMID: 27884767 517. Fujiwara M, Yagi H, Matsuoka R, et al. Implications of mutations of activin receptor-like kinase 1 gene (ALK1) in addition to bone morphogenetic protein receptor II gene (BMPR2) in children with pulmonary arterial hypertension. Circ J 2008; 72: 127- 133. PMID: 18159113 518. Hiraide T, Kataoka M, Suzuki H, et al. SOX17 Mutations in Japanese Patients with Pulmonary Arterial Hypertension. Am J Respir Crit Care Med 2018; 198: 1231-1233. PMID: 30044643 519. Zhu N, Welch CL, Wang J, et al. Rare variants in SOX17 are associated with pulmonary arterial hypertension with congenital heart disease. Genome Med 2018; 10: 56. PMID: 30029678 520. Miyata T, Kimura R, Kokubo Y, et al. Genetic risk factors for deep vein thrombosis among Japanese: importance of protein S K196E mutation. Int J Hematol 2006; 83: 217-223. PMID: 16720551 521. Connors JM. Thrombophilia Testing and Venous Thrombosis. N Engl J Med 2017; 377: 1177-1187. PMID: 28930509 522. Miyawaki Y, Suzuki A, Fujita J, et al. Thrombosis from a prothrombin mutation conveying antithrombin resistance. N Engl J Med 2012; 366: 2390-2396. PMID: 22716977 523. Yoshida R, Seki S, Hasegawa J, et al. Familial pulmonary thromboembolism with a prothrombin mutation and antithrombin resistance. J Cardiol Cases 2018; 17: 197-199. PMID: 30279891 524. Kishimoto M, Suzuki N, Murata M, et al. The first case of antithrombinresistant prothrombin Belgrade mutation in Japanese. Ann Hematol 2016; 95: 541-542. PMID: 26482463 525. Tsuji A, Miyata T, Sekine A, et al. Three Cases of Unprovoked Venous Thromboembolism with Prothrombin p.Arg 596Gln Variant and a Literature Review of Antithrombin Resistance. Intern Med 2023; 62: 885-888. PMID: 35945029 526. Mitsuguro M, Sakata T, Okamoto A, et al. Usefulness of antithrombin deficiency phenotypes for risk assessment of venous thromboembolism: type I deficiency as a strong risk factor for venous thromboembolism. Int J Hematol 2010; 92: 468- 473. PMID: 20859710 527. 門平靖子,森下英理子.DOAC 療法が先天性血栓性素因に及ぼす影響.血栓止血誌 2018; 29: 20-27. 528. Ichiyama M, Ohga S, Ochiai M, et al. Age-specific onset and distribution of the natural anticoagulant deficiency in pediatric thromboembolism. Pediatr Res 2 0 1 6 ; 7 9 : 8 1 - 8 6 . PMID: 26372516 529. Defesche JC, Gidding SS, Harada-Shiba M, et al. Familial hypercholesterolaemia. Nat Rev Dis Primers 2017; 3: 17093. PMID: 29219151 530. Mabuchi H, Koizumi J, Shimizu M, et al. Development of coronary heart disease in familial hypercholesterolemia. Circulation 1989; 79: 225-232. PMID: 2914343 531. Nordestgaard BG, Chapman MJ, Humphries SE, et al. Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society. Eur Heart J 2013; 34: 3478-3490. PMID: 23956253 532. Beheshti SO, Madsen CM, Varbo A, et al. Worldwide Prevalence of Familial Hypercholesterolemia: Meta-Analyses of 11 Million Subjects. J Am Coll Cardiol 2020; 75: 2553- 2566. PMID: 32439005 533. Hu P, Dharmayat KI, Stevens CAT, et al. Prevalence of Familial Hypercholesterolemia Among the General Population and Patients With Atherosclerotic Cardiovascular Disease: A Systematic Review and Meta-Analysis. Circulation 2020; 141: 1742- 1759. PMID: 32468833 534. Makino H, Koezuka R, Tamanaha T, et al. Familial Hypercholesterolemia and Lipoprotein Apheresis. J Atheroscler Thromb 2019; 26: 679-687. PMID: 31231083 535. Ohta N, Hori M, Takahashi A, et al. Proprotein convertase subtilisin/ kexin 9 V4I variant with LDLR mutations modifies the phenotype of familial hypercholesterolemia. J Clin Lipidol 2016; 10: 547-555.e5. PMID: 27206942 536. Mabuchi H, Nohara A, Noguchi T, et al. Hokuriku FH Study Group. Molecular genetic epidemiology of homozygous familial hypercholesterolemia in the Hokuriku district of Japan. Atherosclerosis 2011; 214: 404-407. PMID: 21146822 537. Harada-Shiba M, Arai H, Ohmura H, et al. Guidelines for the Diagnosis and Treatment of Adult Familial Hypercholesterolemia 2022. J Atheroscler Thromb 2023; 30: 558-586. PMID: 36682773 538. Harada-Shiba M, Ohtake A, Sugiyama D, et al. Guidelines for the Diagnosis and Treatment of Pediatric Familial Hypercholesterolemia 2022. J Atheroscler Thromb 2023; 30: 531- 557. PMID: 36682777 539. Talmud PJ, Shah S, Whittall R, et al. Use of low-density lipoprotein cholesterol gene score to distinguish patients with polygenic and monogenic familial hypercholesterolaemia: a case-control study. Lancet 2013; 381: 1293-1301. PMID: 23433573 540. Human Gene Mutation Database. https://www.hgmd.cf.ac.uk/ac/ gene.php?gene=LDLR 541. Tada H, Hori M, Nomura A, et al. A catalog of the pathogenic mutations of LDL receptor gene in Japanese familial hypercholesterolemia. J Clin Lipidol 2020; 14: 346-351. PMID: 32331935 542. Abifadel M, Varret M, Rabès JP, et al. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat Genet 2003; 34: 154-156. PMID: 12730697 543. Harada-Shiba M, Takagi A, Miyamoto Y, et al. Clinical features and genetic analysis of autosomal recessive hypercholesterolemia. J Clin Endocrinol Metab 2003; 88: 2541-2547. PMID: 12788851 544. D’Erasmo L, Minicocci I, Nicolucci A, et al. Autosomal Recessive Hypercholesterolemia: Long-Term Cardiovascular Outcomes. J Am Coll Cardiol 2018; 71: 279-288. PMID: 29348020 545. Nomura A, Okada H, Nohara A, et al. Impact of providing genetics-based future cardiovascular risk on LDL-C in patients with familial hypercholesterolemia. J Clin Lipidol 2023; 17: 622-632. PMID: 37673778 546. Stroes ES, Thompson PD, Corsini A, et al. European Atherosclerosis Society Consensus Panel. Statin-associated muscle symptoms: impact on statin therapy European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management. Eur Heart J 2 0 1 5 ; 3 6 : 1 0 1 2 - 1 0 2 2 . PMID: 25694464 547. Uauy R, Vega GL, Grundy SM, et al. Lovastatin therapy in receptornegative homozygous familial hypercholesterolemia: Lack of effect on low-density lipoprotein concentrations or turnover. J Pediatr 1988; 113: 387-392. PMID: 3397806 548. Stein EA, Honarpour N, Wasserman SM, et al. Effect of the proprotein convertase subtilisin/kexin 9 monoclonal antibody, AMG 1 4 5 , in homozygous familial hypercholesterolemia. Circulation 2013; 128: 2113-2120. PMID: 24014831 549. Yamamoto A, Harada-Shiba M, Kawaguchi A, et al. The effect of